Novel 6-triazolopyridazine sulfanyl benzothiazole derivatives as met inhibitors

A method for treating or preventing cancers;

• said method comprising administering to a patient in need thereof an effective amount of a compound of formula (I):
• wherein:
• represents a single or double bond;
• Ra represents a hydrogen atom;
• a halogen atom;
• an alkoxy radical optionally substituted with a chlorine atom, a hydroxyl radical or a heterocycloalkyl radical;
• an O-cycloalkyl radical;
• heteroaryl radical;
• a phenyl radical;
• an NHCOalk or NHCOcycloalk radical;
• or an NR1R2 radical;
• X represents S, SO or SO2;
• A represents NH or S;
• W represents a hydrogen atom;
• an alkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4;
• or a COR radical in which R represents:
• a cycloalkyl radical or an alkyl radical optionally substituted with an NR3R4, alkoxy, hydroxyl, phenyl, heteroaryl or heterocycloalkyl radical;
• an alkoxy radical optionally substituted with NR3R4, alkoxy, hydroxyl or with heterocycloalkyl;
• an O-phenyl radical or an O—(CH2)n-phenyl radical, and n representing an integer from 1 to 4;
• or an NR1R2 radical;
• in which R1 and R2 are such that one of R1 and R2 represents a hydrogen atom or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from hydroxyl, alkoxy, heteroaryl, heterocycloalkyl, NR3R4 and optionally substituted phenyl radicals, or else R1 and R2 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, N and NH;
• R3 and R4, which may be identical or different, represent a hydrogen atom or an alkyl radical, a cycloalkyl radical, a heteroaryl radical or a phenyl radical that is optionally substituted, or else R3 and R4 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, N and NH;
• all the heterocycloalkyl, heteroaryl and phenyl radicals defined above and also the cyclic radicals that R1 and R2 or R3 and R4 can form with the nitrogen atom to which they are attached, being optionally substituted with one or more radicals chosen from halogen atoms, hydroxyl, oxo, alkoxy, NH2, NHalk and N(alk)2 radicals, alkyl, cycloalkyl, heterocycloalkyl, CH2-heterocycloalkyl, phenyl, CH2-phenyl, heteroaryl, CO-phenyl and S-heteroaryl radicals;
• wherein the alkyl, heterocycloalkyl, phenyl and heteroaryl radicals being themselves optionally substituted with one or more radicals chosen from halogen atoms and the radicals:
• hydroxyl, oxo, alkyl and alkoxy containing from 1 to 4 carbon atoms, NH2, NHalk and N(alk)2;
• wherein the term alkyl means a C1 to C6 alkyl group;
• the term alkoxy means a C1 to C6 alkoxy group;
• the term cycloalkyl means a saturated carbocyclic radical containing 3 to 10 carbon atoms;
• the term heterocycloalkyl means a mono or bicyclic carbocyclic radical containing from 3 to 10 members, interrupted with one or more heteroatoms, which may be the same or different chosen from oxygen, nitrogen or sulphur atoms;
• and the term heteroaryl means a monocyclic or bicyclic unsaturated or partially unsaturated heterocyclic radical containing at most 12 members, which may optionally contain a —C(O)— member and containing one or more heteroatoms which may be the same or different chosen from oxygen, nitrogen or sulphur atoms;
• or the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said compounds.